Healthtech Solutions, Inc. Announces Appointment of Paul Mann to the Board of Directors
NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from pre-clinical to commercial growth, announced today that Paul Mann was appointed to the Board of Directors.
Mann brings over 20 years of experience in the financial and biotechnology industries. He is the Chairman of Varian Biopharmaceuticals (“VarianBio”), an emerging biopharmaceutical company, which was recently acquired by Healthtech that is focused on the development of novel, targeted oncology therapies with transformational potential for cancer patients. Since 2020, he has been engaged as a consultant and analyst for DSAM Partners providing investment advice relating to the healthcare industry. Previously, he served as CFO at PolarityTE, Inc., a biotechnology and regenerative biomaterials company, where he was responsible for all financial operations. Prior to that, Mann was the Healthcare Portfolio Manager at Highbridge Capital Management and has held positions with Soros Fund Management, UBS Investment Group, Morgan Stanley and Deutsche Bank. He began his career as a scientist at Procter and Gamble and is named as an inventor on patents for skincare compounds and technologies. Mann has an MA (Cantab) and an MEng from Cambridge University, where he studied natural sciences and chemical engineering, and is a CFA charter holder.
“I’m genuinely excited to join the board of directors of Healthtech because I believe their portfolio business model leverages my intrinsic strengths and experience,” Mann stated. “I have spent the vast majority of my career evaluating and investing in promising healthcare companies, and I believe the business model at Healthtech can provide significant value to its subsidiary companies well beyond what’s possible in traditional investment approaches. The leadership, networks and operational support that can be provided to portfolio companies creates distinct advantages as they focus on building fundamental value.”
Ned Swanson, MD, CEO of Healthtech, commented, “Paul’s addition to the board of directors will be invaluable as we execute on our vision to build the next portfolio-model life sciences company. Not only is his background in the financial and biotechnology industries directly applicable to our mission, but his perspective as Chairman of VarianBio will inform the leadership of Healthtech how to continuously improve our model.”
About Healthtech Solutions Inc.
Healthtech Solutions Inc. is an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through our subsidiary companies ranging in stage from pre-clinical to commercial growth. At Healthtech, we are driven by innovation and people. At the core, our philosophy is that highly motivated people with ambitious goals can achieve breakthroughs with the right organizational support. By identifying and building visionary teams within an ecosystem that fuels their strengths, we believe that we can collectively accelerate the next wave of advancements in healthcare. From our perspective, breakthroughs often occur at the intersection of multiple approaches, so we are agnostic to the solution - therapeutics, devices, diagnostics, digital technology, or a combination. In fact, we hypothesize that some of the most promising breakthroughs will occur at the interface of these traditional silos, which has already begun to occur. Healthcare, illness, and injury are multifactorial, and we believe the solutions often need to be multi-pronged to succeed.
NO OFFER OR SOLICITATION
This communication shall neither constitute an offer to sell nor the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, over many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Upcoming Life Sciences Events
- August 2021
- Biotechgate Digital Partnering
- September 2021
- Swiss Biotech Day 2021
- Digital RESI